DA
GPCR icon

DCF Advisers’s Structure Therapeutics GPCR Stock Holding History

DCF Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
32,100
+4,600
+17% +$204K 0.3% 53
2026
Q1 		$1.33M Sell
27,500
-2,500
-8% -$171K 0.35% 49
2025
Q4 		$2.09M Buy
+30,000
New +$1.22M 0.56% 46
2025
Q3 		– Sell
-24,750
Closed -$513K – 108
2025
Q2 		$513K Buy
+24,750
New +$544K 0.24% 68

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DCF Advisers's GPCR Position: Q2 2026 in Review

DCF Advisers increased its Structure Therapeutics (GPCR) stake by 17% in Q2 2026, buying an estimated $204K and bringing the position to 32,100 shares worth $1.72M. The position accounts for 0.3% of the portfolio, ranked #53.

DCF Advisers first reported a position in GPCR in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.09M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • DCF Advisers held 32,100 shares of Structure Therapeutics worth $1.72M as of Q2 2026.
  • DCF Advisers bought 4,600 Structure Therapeutics shares in Q2 2026, an estimated $204K.
  • Structure Therapeutics made up 0.3% of DCF Advisers's portfolio in Q2 2026, its #53 holding.
  • DCF Advisers first reported a position in Structure Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • DCF Advisers's Structure Therapeutics position peaked at $2.09M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.